We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biodynamics Plc | LSE:OBD | London | Ordinary Share | GB00BD5H8572 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.02 | 0.23% | 8.85 | 289,012 | 16:35:26 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 8.70 | 9.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 1.34M | -10.83M | -0.0535 | -1.65 | 17.86M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:15:53 | O | 88 | 9.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 11/4/2024 | 14:36 | UK RNS | Oxford BioDynamics PLC Holding(s) in Company |
| 10/4/2024 | 16:28 | UK RNS | Oxford BioDynamics PLC Holding(s) in Company |
| 09/4/2024 | 17:35 | UK RNS | Oxford BioDynamics PLC Holding(s) in Company |
| 09/4/2024 | 12:42 | UK RNS | Oxford BioDynamics PLC Holding(s) in Company |
| 09/4/2024 | 11:56 | UK RNS | Oxford BioDynamics PLC Holding(s) in Company |
| 05/4/2024 | 16:52 | UK RNS | Oxford BioDynamics PLC Holding(s) in Company |
| 05/4/2024 | 08:28 | UK RNS | Oxford BioDynamics PLC Holding(s) in Company |
| 03/4/2024 | 14:31 | ALNC |  Oxford BioDynamics reaches "important milestone" with new laboratory |
| 03/4/2024 | 12:57 | UK RNS | Oxford BioDynamics PLC Results of GM |
| 03/4/2024 | 07:00 | UK RNS | Oxford BioDynamics PLC OBD opens UK clinical testing facility |
Oxford Biodynamics (OBD) Share Charts1 Year Oxford Biodynamics Chart |
|
1 Month Oxford Biodynamics Chart |
Intraday Oxford Biodynamics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 05/4/2024 | 10:20 | OBD without the muppets | 192 |
| 13/3/2024 | 18:27 | Oxford BioDynamics PLC | 1,685 |
| 15/1/2024 | 20:55 | OBD-23/03/21-110P-SP might go up exponentially given the potential in the US | 52 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:15:53 | 9.00 | 88 | 7.92 | O |
| 15:15:53 | 9.00 | 666 | 59.94 | O |
| 14:02:09 | 8.89 | 2,249 | 199.94 | O |
| 13:34:38 | 8.75 | 111,111 | 9,726.66 | O |
| 13:23:26 | 8.75 | 1,000 | 87.54 | O |
| Top Posts |
|---|
Posted at 16/4/2024 09:20 by Oxford Biodynamics Daily Update Oxford Biodynamics Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker OBD. The last closing price for Oxford Biodynamics was 8.83p.Oxford Biodynamics currently has 202,303,415 shares in issue. The market capitalisation of Oxford Biodynamics is £17,863,392. Oxford Biodynamics has a price to earnings ratio (PE ratio) of -1.65. This morning OBD shares opened at - |
Posted at 13/3/2024 17:45 by smithie6 And the chart says it all.Listed in ~2007 & the share price has fallen by miles....& now raising money at a low. A successful company would raise money at higher prices. |
Posted at 20/2/2024 01:11 by bones698 At the end of the day they need to turn it into money and a profitable business and thus far are failing to do that. Many companies struggle at this stage to turn promise into cash and when they are so. Loss making like obd it means they are required to raise capital at ever lower prices. In this market that resits in an share price that gets hammered and ehyvobd is struggling as everyone knows its coming.Getting a deal with a large upfront payment at this stage is unlikely but a small one won't provide enough runeya to see a profit and so a rights issue is the most likely outcome at a big discount given the amount they are likely to require. Sad but true for many small companies atm |
Posted at 29/1/2024 17:26 by bones698 If they leave it to the last minute this will tank big time m they already left it too late and look what's happening . Now be lucky to get it away for 10p . If you look back I warned about this happening and now it's in the funding spiral as everyone knows it's coming so the pressure is on the share price . Also once they go to the city whoever is providing the funds will forward sell to make their money back .So either they have done that and that's why the price is falling or if not this could get very painful indeed once they do . Needing capital in these markets kills shareprices just look around . Ignoring the facts and burying your head in the sand won't stop what's coming |
Posted at 19/1/2024 20:43 by bones698 I doubt they have enough time to construct such a deal as they can take upto a year to complete and they need funds for sooner than that . Unfortunately that then means a fund raise on the open market is most likely and that will be at a discount . The market seems to agree with this and is marking the price down accordingly . The longer they leave it to do the lower the share price and rights issue price is likely to be . Judging by the shareprice they might have already approached the market so anywhere from 10-15p fund raise looks likely as it's not stopped falling yet . Funders also tend to forward sell the shares to recoup their money that way . |
Posted at 08/12/2023 10:10 by bigruss1 Oxford, UK - 2 AUGUST 2023 - Oxford BioDynamics PLC (AIM: OBD, "OBD", the "Company" and, together with its subsidiaries, the "Group"), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, is pleased to announce that it has successfully raised gross proceeds of £5.6m pursuant to a placing, conducted via an accelerated bookbuild process (the "Placing") and through direct subscriptions (the "Subscription").Conditionally, in aggregate, 48,120,790 new ordinary shares of 1p ("Ordinary Shares") each in the Company will therefore be issued pursuant to the Placing (the "Placing Shares") at an issue price of 11p per new Ordinary Share ("Issue Price"). The Placing comprised both a General Placing and a VCT/EIS Placing. Subscribers have conditionally subscribed for, in aggregate, 2,528,634 new Ordinary Shares (the "Subscription Shares") at the Issue Price. In addition, retail investors are able to participate via the PrimaryBid platform (the "PrimaryBid Offer", and together with the Placing and the Subscription, the "Fundraising"). The PrimaryBid Offer remains open. Further details on the results of the PrimaryBid Offer will be announced separately. The Placing Shares and Subscription Shares represent approximately 25.7 per cent. of the Company's issued ordinary share capital as enlarged by the Placing and Subscription. Shore Capital and Baden Hill acted as joint brokers and bookrunners in connection with the Placing. Its clear to me there is still alot of share to flip and the downward trend will continue unlucky really for those spiked here ..Big sell off under way |
Posted at 20/11/2023 10:40 by hatfullofsky I also sent the following mail to OBD.I was pleased to read the article in the Daily Mail on 18th November, which is great news for the patient and possibly good news for OBD. I am a shareholder of OBD and would like to know if OBD's PSE test will be included in the the TRANSFORM screening pilot ? I would also like to hear your views of how this screening proposal may effect the adoption of the PSE test ? Clearly if there is a preferred screening approach that does not include the PSE test it would be hard to gain test adoption. Regards |
Posted at 27/10/2023 14:28 by paxman 'Smithie6I've put money today in to Nat West. p/e of 4 More attractive risk/reward imo. And nett tang. assets per share higher than the share price.' You're not calculating risk v reward correctly Smithie. Nat West may well go up. But you'll be lucky to double your money over the next few years. So say a 50% probability of making 100% i.e. an expected return of 50%. OBD needs only to get 5% of the CiRT market. Why wouldn't a patient and clinician want to know if immunotherapy is likely to work ? And why wouldn't an insurer want to have confidence the $75,000 course of therapy it's costing them is likely to be effective. OBD only needs 1% of PSA testers to use the PSE test. Once again why wouldn't patients, doctors and insurers want more information and guidance in critical situation. If OBD achieve the above in only the US - and we know they are already in the UK through BUPA - you 10 times your money. Calcs - 5% of CiRT market is 33,000 patients a year. At $2200 a CiRT test at 75% margin gives $ 54,000 profit. 1% of 25 m a year PSA testers gives 250,000. At $ 400 a test at 50% margin gives $ 100 m revenue and $ 50 m profit. So $ 100 m combined profit with say £ 10 m a year corporate overhead gives £ 70m profit or say £ 700m of market cap. That's 10 times the current cap. So you are saying it is twenty times more likely Nat West's PE ration will double than 5% of immunotherapy stakeholders will want very important, life critical, information and 1% of PSA testers will want the same. That's incredibly unlikely. |
Posted at 26/10/2023 15:46 by smithie6 Blah blah blah.OBD has not created a yes/no test for prostate cancer. Full stop. If it had its share price would be much higher. ....if potential shareholders need to first have a degree in human pharma stuff & read the OBD test reports & understand words like "epigenetic biomarkers" Then the number of potential shareholders in the UK where OBD is listed is quite small. I'm not interested to devote the time to learn about all this medical jargon such as "epigenetic biomarkers". I note the words genetic & surveillance of people that have been tested. If OBD come up with a yes/no test for prostate cancer then I would be interested to again buy/hold some shares. ----- Usual low quality of posts on ADVFN. 'you don't like the shares so I'm going to slag you off' Infers that some posters are not very shrewd/wise. |
Posted at 03/10/2023 17:57 by czar OBD will make at least £500 per test, that is profit not sales and is after all costs. Agreed the NHS will get a discount but there is demand for 8m tests in the UK and OBD will have no capacity for the UK for quite a while and even then only 200,000 pa which is 2.5% of the tests required. By the time OBD is serving the NHS they will be doing millions of tests in the USA and millions more around the world. There will be plenty of US companies trying to buy OBD out long before they get that far. I just hope it doesn't get sold cheap like so many great British companies. Even after the rise over the last few days this company is valued at a fraction of its true worth IMHO. Anyway BUY it, SELL it, do whatever, people on here will make no difference to this share price. |
Posted at 03/10/2023 10:21 by intoodeep 2018 Share Price £2.30Shares In Issue 92,546,138 Market Cap £212,856,117 2023 Share Price £0.41 Shares In Issue 202,338,236 Market Cap £82,958,677 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
